Estratificación del riesgo para la toma de decisiones en revascularización miocárdica

Palabras clave: Toma de Decisiones, Revascularización Miocárdica, Evaluación de Riesgo, Cardiología

Resumen

La enfermedad arterial coronaria crónica es una de las causas principales de muerte a nivel mundial. La revascularización miocárdica, a través de la intervención coronaria percutánea o la cirugía de bypass aortocoronario, es un pilar fundamental del tratamiento, y la decisión de su elección debe ser realizada por un equipo multidisciplinario, que considere los riesgos y beneficios inherentes a cada estrategia. Múltiples escalas de riesgo pronóstico, con ventajas y limitaciones, son usadas en la práctica clínica. El propósito de la presente revisión es proveer información que pueda ayudar a la estratificación del riesgo y la toma de decisiones individualizadas.

Descargas

La descarga de datos todavía no está disponible.

Citas

Piccolo R, Giustino G, Mehran R, Windecker S. Stable coronary artery disease: revascularization and invasive strategies. Lancet 2015; 386: 702–13.

Stirrup J, Velasco A, Hage FG, Reyes E. Comparison of ESC and ACC/AHA guidelines for myocardial revascularization. J Nucl Cardiol 2017;24:1046–53.

Josef F, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, et al. Guía ESC/EACTS 2018 sobre revascularización miocárdica. Rev Esp Cardiol. 2019;72(1):73.e1-e102.

Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, et al. Guía de práctica clínica de la ESC sobre revascularización miocárdica, 2014. Rev Esp Cardiol. 2015;68(2):144.e1–e95.

Garg S, Holmes DR. Risk stratification and risk models in revascularization. The PCR – EAPCI Texbook. Percutaneus Interventional Cardiovascular Medicine. Part III.

Nashef SA, Roques F, Michel P, Gauducheau E, Lemeshow S, Salamon R. European system for cardiac operative risk evaluation (EuroSCORE). Eur J Cardiothorac Surg. 1999;16:9-13.

Toumpoulis IK, Anagnostopoulos CE, DeRose JJ, Swistel DG. European system for cardiac operative risk evaluation predicts long-term survival in patients with coronary artery bypass grafting. Eur J Cardiothorac Surg. 2004;25:51-58.

Kim YH, Ahn JM, Park DW, Lee BK, Lee CW, Hong MK, et al. EuroSCORE as a predictor of death and myocardial infarction after unprotected left main coronary stenting. Am J Cardiol. 2006;98:1567-1570.

Morice MC, Serruys PW, Kappetein AP, Feldman TE, Stahle E, Colombo A, et al. Outcomes in patients with de novo left main disease treated with either percutaneous coronary intervention using paclitaxel-eluting stents or coronary artery bypass graft treatment in the Synergy Between Percutaneous Coronary Intervention with TAXUS and Cardiac Surgery (SYNTAX) trial. Circulation. 2010;121:2645-2653.

Min SY, Park DW, Yun SC, Kim YH, Lee JY, Kang SJ, et aL. Major predictors of long-term clinical outcomes after coronary revascularization in patients with unprotected left main coronary disease: analysis from the MAIN-COMPARE study. Circ Cardiovasc Interv. 2010;3:127-133.

Rodes-Cabau J, Deblois J, Bertrand OF, Mohammadi S, Courtis J, Larose E, et al. Nonrandomised comparison of coronary artery bypass surgery and percutaneous coronary intervention for the treatment of unprotected left main coronary artery disease in octogenarians. Circulation. 2008;118:2374-2381.

Kim Y-H, Park D-W, Kim W-J, Lee J-Y, Yun S-C, Kang S-J, et al. Validation of SYNTAX (Synergy between PCI with Taxus and Cardiac Surgery) Score for Prediction of Outcomes After Unprotected Left Main Coronary Revascularization. J Am Coll Cardiol Intv. 2010;3:612-623.

Onuma Y, Girasis C, Piazza N, Garcia-Garcia HM, Kukreja N, Garg S, on behalf of Interventional Cardiologists at Thoraxcenter. Long-Term Clinical Results Following Stenting of the Left Main Stem: Insights From RESEARCH (Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated at Rotterdam Cardiology Hospital) Registries. J Am Coll Cardiol Intv. 2010;3:584-594.

Serruys PW, Onuma Y, Garg S, Vranckx P, De Bruyne B, Morice MC, et al. 5-Year Clinical Outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the Sirolimus-Eluting Stent in the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions. J Am Coll Cardiol. 2010;55:1093-1101.

Nashef SAM, Roques F, Sharples LD, Nilsson J, Smith C, Goldstone AR, et al. EuroSCORE II. Eur J Cardiothorac Surg 2012;41(4):734–4.

Guida P, Mastro F, Scrascia G, Whitlock R, Paparella D. Performance of the European System for Cardiac Operative Risk Evaluation II: a metaanalysis of 22 studies involving 145,592 cardiac surgery procedures. J Thorac Cardiovasc Surg 2014;148(6):3049–57.e1.

Dewey TM, Brown D, Ryan WH, Herbert MA, Prince SL, Mack MJ. Reliability of risk algorithms in predicting early and late operative outcomes in high-risk patients undergoing aortic valve replacement. J Thorac Cardiovasc Surg. 135:180-7, 2008.

Osnabrugge RL, Speir AM, Head SJ, Fonner CE, Fonner E, Kappetein AP, et al. Performance of EuroSCORE II in a large US database: Implications for transcatheter aortic valve implantation. EurJ Cardiothorac Surg. 2014;46:400–408.

Sullivan PG, Wallach JD, Ioannidis JP. Meta-analysis comparing established risk prediction models (EuroSCORE II, STS Score, and ACEF Score) for perioperative mortality during cardiac surgery. Am J Cardiol. 2016;118:1574–1582.

Kirmani BH, Mazhar K, Fabri BM, Pullan DM. Comparison of the EuroSCORE II and Society of Thoracic Surgeons 2008 risk tools. EurJ Cardiothorac Surg. 2013;44:999–1005.

Granton J, Cheng D. Risk stratification models for cardiac surgery. Semin Cardiothorac Vasc Anesth 2008;12(3):167–74.

Brennan JM, Curtis JP, Dai D, Fitzgerald S, Khandelwal AK, Spertus JA, et al. Enhanced mortality risk prediction with a focus on high-risk percutaneous coronary intervention: results from 1,208,137 procedures in the NCDR (National Cardiovascular Data Registry). JACC Cardiovasc Interv. 2013 Aug;6(8):790-9.

Peterson ED, Dai D, DeLong ER, Brennan JM, Singh M, Rao SV, et al. Contemporary Mortality Risk Prediction for Percutaneous Coronary Intervention: Results From 588,398 Procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol. 2010;55:1923-1932.

Ranucci M, Castelvecchio S, Conte M, Megliola G, Speziale G, Fiore F, et al. The easier, the better: age, creatinine, ejection fraction score for operative mortality risk stratification in a series of 29,659 patients undergoing elective cardiac surgery. J Thorac Cardiovasc Surg. 2011;142:581-586.

Sullivan PG, Wallach JD, Ioannidis JP. Meta-Analysis Comparing Established Risk Prediction Models (EuroSCORE II, STS Score, and ACEF Score) for Perioperative Mortality During Cardiac Surgery. Am J Cardiol. 2016 Nov 15;118(10):1574-1582.

Wykrzykowska JJ, Garg S, Onuma Y, de Vries T, Goedhart D, Morel MA, et al. Value of age, creatinine, and ejection fraction (ACEF score) in assessing risk in patients undergoing percutaneous coronary interventions in the 'All-Comers' LEADERS trial. Circ Cardiovasc Interv. 2011;4:47-56.

Sianos G, Morel MA, Kappetein AP, Morice MC, Colombo A, Dawkins K, et al. The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. EuroIntervention. 2005;1:219-227.

Serruys PW, Onuma Y, Garg S, Sarno G, van den Brand M, Kappetein AP, et al. Assessment of the SYNTAX score in the Syntax study. EuroIntervention. 2009;5:50-56.

Capodanno D, Di Salvo ME, Cincotta G, Miano M, Tamburino C, Tamburino C. Usefulness of the SYNTAX Score for Predicting Clinical Outcome After Percutaneous Coronary Intervention of Unprotected Left Main Coronary Artery Disease. Circ Cardiovasc Intervent. 2009;2:302-308.

Wykrzykowska J, Garg S, Girasis C, de Vries T, Morel MA, van Es GA, et al. Value of the Syntax Score (SX) for Risk Assessment in the “All-comers” Population of the Randomised Multicenter Leaders Trial. J Am Coll Cardiol. 2010;56:272-277.

Garg S, Sarno G, Serruys PW, Rodriguez AE, Bolognese L, Anselmi M, et al. Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolimus-Eluting Stent Versus Abciximab and Bare-Metal Stent in Acute Myocardial Infarction) and MULTISTRATEGY (Multicenter Evaluation of Single High-Dose Bolus Tirofiban Versus Abciximab With Sirolimus-Eluting Stent or Bare-Metal Stent in Acute Myocardial Infarction Study) trials. JACC Cardiovasc Interv. 2011;4:66-75.

Garg S, Serruys PW, Silber S, Wykrzykowska J, van Geuns RJ, Richardt G, et al. The prognostic utility of the SYNTAX score on 1-year outcomes after revascularization with zotarolimus- and everolimus-eluting stents: a substudy of the RESOLUTE All Comers Trial. JACC Cardiovasc Interv. 2011;4:432-441.

Garg S, Sarno G, Girasis C, Vranckx P, de Vries T, Swart M, et al. A patient-level pooled analysis assessing the impact of the SYNTAX (synergy between percutaneous coronary intervention with taxus and cardiac surgery) score on 1-year clinical outcomes in 6,508 patients enrolled in contemporary coronary stent trials. JACC Cardiovasc Interv. 2011;4:645-653.

Genereux P, Palmerini T, Caixeta A, Rosner G, Green P, Dressler O, et al. Quantification and impact of untreated coronary artery disease after percutaneous coronary intervention: the residual SYNTAX (Synergy Between PCI with Taxus and Cardiac Surgery) score. J Am Coll Cardiol. 2012;59:2165-2174..

Farooq V, Serruys PW, Bourantas CV, Zhang Y, Muramatsu T, Feldman T, et al. Quantification of incomplete revascularization and its association with five-year mortality in the synergy between percutaneous coronary intervention with Taxus and cardiac surgery (SYNTAX) trial validation of the residual SYNTAX score. Circulation. 2013;128:141-151.

Nam CW, Mangiacapra F, Entjes R, Chung IS, Sels JW, Tonino PA, et al. Functional SYNTAX score for risk assessment in multivessel coronary artery disease. J Am Coll Cardiol. 2011;58:1211-1218.

Capodanno D, Miano M, Cincotta G, Caggegi A, Ruperto C, Bucalo R, et al. EuroSCORE refines the predictive ability of SYNTAX score in patients undergoing left main percutaneous coronary intervention. Am Heart J. 2010;159:103-109.

Capodanno D, Caggegi A, Miano M, Cincotta G, Dipasqua F, Giacchi G, et al. Global risk classification and clinical SYNTAX (synergy between percutaneous coronary intervention with TAXUS and cardiac surgery) score in patients undergoing percutaneous or surgical left main revascularization. JACC Cardiovasc Interv. 2011 Mar;4(3):287-97.

Serruys P, Farooq V, Vranckx P, Girasis C, Salvatore B, García – García H, et al. A global risk approach to identify patients with left main or 3 vessel disease who could safely and efficaciously be treated with percutaneus coronary intervention: The SYNTAX trial at 3 years. JACC Cardiovasc Interv. 2012 Jun; 5(6): 606 – 617.

Farooq V, van Klaveren D, Steyerberg EW, Meliga E, Vergouwe Y, Chieffo A, et al. Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet. 2013;381:639-50.

Waldo S, Secemsky E, O'Brien C, Kennedy K, Pomerantsev E, Sundt T, et al. Surgical Ineligibility and Mortality Among Patients with Unprotected Left Main or Multivessel Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. Circulation. 2014 Dec 23; 130(25): 2295–2301.

Publicado
2019-07-10
Cómo citar
1.
Custodio-Sánchez P. Estratificación del riesgo para la toma de decisiones en revascularización miocárdica. Rev Peru Investig Salud [Internet]. 10jul.2019 [citado 17ene.2020];3(3):133-42. Available from: http://revistas.unheval.edu.pe/index.php/repis/article/view/336
Sección
Artículos de revisión